Low HDL-cholesterol: a strong predictor of glycemic response to glitazone treatment in patients with type 2 diabetes

Diabetes Res Clin Pract. 2011 Jul;93(1):e44-8. doi: 10.1016/j.diabres.2011.04.005. Epub 2011 May 6.

Abstract

We performed a study in 102 people with type 2 diabetes aiming to determine "easy-to-use" predictive factors for glycemic response to glitazones. We found that low baseline HDL-cholesterol (<40 mg/L [1.04 mmol/L] in males, <50 mg/L [1.30 mmol/L] in females) was a strong independent predictor of glycemic response to glitazones (OR=2.67 [2.02-3.52], p=0.0004).

Trial registration: ClinicalTrials.gov NCT00953498.

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / drug effects
  • Cholesterol, HDL / blood*
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Female
  • Glycated Hemoglobin / metabolism
  • Humans
  • Male
  • Middle Aged
  • Pioglitazone
  • Prospective Studies
  • Rosiglitazone
  • Thiazolidinediones / therapeutic use*

Substances

  • Blood Glucose
  • Cholesterol, HDL
  • Glycated Hemoglobin A
  • Thiazolidinediones
  • Rosiglitazone
  • Pioglitazone

Associated data

  • ClinicalTrials.gov/NCT00953498